KALA Kala Pharmaceuticals, Inc.

NASDAQ
$0.57

Kala Pharmaceuticals, Inc. (KALA) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal In line Selling ran in line with KALA's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 0 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
6
10 transactions
Purchases
$0
0 shares
Sales
$1.3M
1,033,821 shares
Net activity
-$1.3M
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $0 0 transactions · 0 shares
Discretionary sales $1.3M 10 transactions · 1,033,821 shares

Largest single sale: $640.7K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Iwicki Mark T Director Sell 154,894 $0.81 $125.5K 103,540 −59.9% of holding
Reumuth Mary CHIEF FINANCIAL OFFICER Sell 967 $0.82 $793 28,906 −3.2% of holding
Bazemore Todd Director Sell 47,768 $0.83 $39.6K 35,932 −57.1% of holding
Brazzell Romulus K SEE REMARKS Sell 46,748 $0.83 $38.8K 35,952 −56.5% of holding
Reumuth Mary CHIEF FINANCIAL OFFICER Sell 32,230 $0.83 $26.8K 29,873 −51.9% of holding
Kharabi Darius CHIEF BUSINESS OFFICER Sell 20,806 $0.83 $17.3K 41,760 −33.3% of holding
2 fills Sell 513,607 $1.38 $710.7K 425,006 −54.7% of holding
2 fills Sell 216,801 $1.60 $346.0K 887,973 −19.6% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.